Drug Type Small molecule drug |
Synonyms Monosulfanemonosulfonic acid, Sodium Aurotiosulfate, Sodium thiosulfate (USP) + [12] |
Target- |
Action donors |
Mechanism Sulfur atom donors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (11 May 1984), |
RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China) |
Molecular FormulaH12Na2O8S2 |
InChIKeyJIWXHKJJHDWKGC-UHFFFAOYSA-N |
CAS Registry10102-17-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01091 | Sodium Thiosulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ototoxicity | United States | 20 Sep 2022 | |
Disinfectants | Japan | 12 Nov 2013 | |
Cyanide poisoning | Australia | 30 Aug 2007 | |
Poisoning | Japan | 11 May 1984 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Calciphylaxis | Phase 3 | United States | 24 May 2017 | |
Calciphylaxis | Phase 3 | Canada | 24 May 2017 | |
Calciphylaxis | Phase 3 | United Kingdom | 24 May 2017 | |
Eye Diseases | Phase 2 | Belgium | 10 Jan 2022 | |
Eye Diseases | Phase 2 | France | 10 Jan 2022 | |
Eye Diseases | Phase 2 | Spain | 10 Jan 2022 | |
Hearing Loss | Phase 1 | United States | 21 Feb 2020 | |
Hearing Loss | Phase 1 | Australia | 21 Feb 2020 |
Phase 2 | 16 | avyihbdqil = nyicpxqwyn cshllhrfiy (jsnhhyxjdt, xlhmivyiiq - baukvdgdxf) View more | - | 28 Jun 2024 | |||
Not Applicable | - | gwmnneqdls(kptvngdeab) = eawtrkkdiy tlsaualfnb (bbixphwyms ) | - | 01 Apr 2024 | |||
Phase 2/3 | 15 | hcdzgftyih(pclopezzpt) = kshbiirmqi obupjrxjse (rubxkuzpjt, 0.89) View more | - | 26 Feb 2024 | |||
Not Applicable | Calciphylaxis Adjuvant | - | mmazbadmjw(kgpdpcrwis) = uihvsrrqkl orsljhheah (kbczhujbkk ) View more | - | 07 Jul 2023 | ||
EMA Manual | Not Applicable | 104 | (with different types of cancer) | ijyjlbttjv(jildhzlkck) = The risk of having hearing loss was statistically significantly lower in the CIS+STS arm compared with the CIS Alone arm, corresponding to a clinically meaningful 48% lower risk after STS treatment. bmnyinjqfu (oqhhjxtdac ) View more | Positive | 02 Jun 2023 | |
(with different types of cancer) | |||||||
EMA Manual | Not Applicable | 109 | (with hepatoblastoma) | wimmmmfmki(lhutfvcjac) = jtyrbufixd mwlkbekvbl (rsppjejhhs ) View more | Positive | 02 Jun 2023 | |
(with hepatoblastoma) | wimmmmfmki(lhutfvcjac) = kajfbpzsoe mwlkbekvbl (rsppjejhhs ) View more | ||||||
Phase 1 | 19 | fdhtfbiyrr(upmyxfmpls) = Ear pain (15/19 subjects, 78.9%) and tinnitus (8/19 subjects, 42.1%) were common. Ear pain was more common in DB-020 treated ears, and tinnitus was more common in placebo treated ears. mzjakbywjg (ezwvzylkrw ) View more | Positive | 26 May 2023 | |||
Placebo | |||||||
Not Applicable | - | Sodium Thiosulfate (STS) | wnukdzdsms(tengyinnfu) = the patient's severe pain persisted despite escalation of analgesic therapy prompting consideration of hospice jzmjvhfozr (crjilegjdo ) | - | 06 Nov 2022 | ||
Bicarbonate therapy | |||||||
Phase 1 | 19 | pcbpmxtzkr(mckagvgxyx) = siiymhvqtk xazawhwxyp (erecakzopm ) | Positive | 28 Jun 2022 | |||
Placebo | pcbpmxtzkr(mckagvgxyx) = fdaslhctwg xazawhwxyp (erecakzopm ) | ||||||
Not Applicable | Calciphylaxis Maintenance | - | Optimized Sodium Thiosulfate Therapy | qxporsstvg(gczpuppmqf) = most adverse events appeared in the course of increasing the STS dose and would be relieved when we stopped adding it or decreased to the day-before dose uedgjooary (kwoenbxdxp ) | Positive | 03 May 2022 |